



September 11, 2018

BSE Limited 1st Floor, P J Towers, Dalal Street, Mumbai-40001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated September 11, 2018 titled "Zydus receives tentative approval from the USFDA for Sitagliptin Tablets".

The contents of the press release give full details.

AHMEDABAD

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

UPEN H. SHAH COMPANY SECRETARY

Encl.: As above

Regd. Office: 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015, India.

Phone: +91-79-2686 8100 (20 lines) www.zyduscadila.com CIN: L24230GJ1995PLC025878



Press Release

Press Release

Zydus receives tentative approval from the USFDA for Sitagliptin Tablets

THIS RELEASE

Ahmedabad, 11 September, 2018

Zydus Cadila has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg (US RLD – Januvia® Tablets). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.

The group now has 217 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
